AstraZeneca and Fresenius Medical Care will exit the kidney disease treatment developer in a $725m acquisition that could potentially rise to $2.1bn.

Pharmaceutical firm Novo agreed yesterday to purchase US-based genomics therapy developer Corvidia Therapeutics for up to $2.1bn, enabling pharmaceutical firm AstraZeneca and kidney dialysis equipment producer Fresenius Medical Care to exit. The deal will involve a $725m cash payment upfront but could potentially top out at $2.1bn if every regulatory and sales milestone is achieved…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.